All Studies Meta Analysis Recent:

Vitamin C promotes ACE2 degradation and protects against SARS‐CoV‐2 infection

Zuo et al., EMBO reports, doi:10.15252/embr.202256374 (date from preprint)

Jul 2022

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Vitamin C for COVID-19

6th treatment shown to reduce risk in September 2020

^*, now with p = 0.000000028 from 72 studies, recognized in 12 countries.

Lower risk for mortality, ICU admission, hospitalization, and recovery.

No treatment is 100% effective. Protocols combine treatments. ^* >10% efficacy, ≥3 studies.

4,500+ studies for 81 treatments. c19early.org

In Vitro and mouse study showing that vitamin C inhibits SARS-CoV-2. Vitamin C lowered ACE2 protein levels in a dose-dependent manner at a concentration of 1-10mM in both cell and humanized ACE2 mouse models.

13 preclinical studies support the efficacy of vitamin C for COVID-19:

6 In Silico studies1-6

6 In Vitro studies5,7-11

1 In Vivo animal study9

Vitamin C has been identified by the European Food Safety Authority (EFSA) as having sufficient evidence for a causal relationship between intake and optimal immune system function12-14. Vitamin C plays a key role in the immune system, supporting the production and function of leukocytes, or white blood cells, which defend against infection and disease, including the production of lymphocytes, which make antibodies, and enhancing phagocytosis, the process by which immune system cells ingest and destroy viruses and infected cells. Vitamin C is an antioxidant, protecting cells from damage caused by free radicals. Vitamin C inhibits SARS-CoV-2 3CL^pro5,8 and inhibits SARS-CoV-2 infection by reducing ACE2 levels in a dose-dependent manner9. Intracellular levels of vitamin C decline during COVID-19 hospitalization suggesting ongoing utilization and depletion of vitamin C15. Threonic acid, a metabolite of vitamin C, is lower in mild and severe cases, consistent with increased need for and metabolization of vitamin C with moderate infection, but more limited ability to produce threonic acid in severe infection due to depletion or existing lower levels of vitamin C16. Symptomatic COVID-19 is associated with a lower frequency of natural killer (NK) cells, and vitamin C has been shown to improve NK cell numbers and functioning17,18.

Important missing comments or errors? Let us know.

1. Agamah et al., Network-based multi-omics-disease-drug associations reveal drug repurposing candidates for COVID-19 disease phases, ScienceOpen, doi:10.58647/DRUGARXIV.PR000010.v1.scienceopen.com, doi.org.

2. Morales-Bayuelo et al., New findings on ligand series used as SARS-CoV-2 virus inhibitors within the frameworks of molecular docking, molecular quantum similarity and chemical reactivity indices, F1000Research, doi:10.12688/f1000research.123550.3.f1000research.com, doi.org.

3. Alkafaas et al., A study on the effect of natural products against the transmission of B.1.1.529 Omicron, Virology Journal, doi:10.1186/s12985-023-02160-6.biomedcentral.com, doi.org.

4. Pandya et al., Unravelling Vitamin B12 as a potential inhibitor against SARS-CoV-2: A computational approach, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2022.100951.sciencedirect.com, doi.org.

5. Malla et al., Vitamin C inhibits SARS coronavirus-2 main protease essential for viral replication, bioRxiv, doi:10.1101/2021.05.02.442358.biorxiv.org, doi.org.

6. Kumar et al., In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19, VirusDisease, doi:10.1007/s13337-020-00643-6.springer.com, doi.org.

7. Moatasim et al., Potent Antiviral Activity of Vitamin B12 against Severe Acute Respiratory Syndrome Coronavirus 2, Middle East Respiratory Syndrome Coronavirus, and Human Coronavirus 229E, Microorganisms, doi:10.3390/microorganisms11112777.mdpi.com, doi.org.

8. Đukić et al., Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination, Frontiers in Bioscience-Landmark, doi:10.31083/j.fbl2801008.imrpress.com, doi.org.

9. Zuo et al., Vitamin C promotes ACE2 degradation and protects against SARS‐CoV‐2 infection, EMBO reports, doi:10.15252/embr.202256374.wiley.com, doi.org.

10. Hajdrik et al., In Vitro Determination of Inhibitory Effects of Humic Substances Complexing Zn and Se on SARS-CoV-2 Virus Replication, Foods, doi:10.3390/foods11050694.mdpi.com, doi.org.

11. Goc et al., Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants, European Journal of Microbiology and Immunology, doi:10.1556/1886.2021.00022.akjournals.com, doi.org.

12. Galmés et al., Suboptimal Consumption of Relevant Immune System Micronutrients Is Associated with a Worse Impact of COVID-19 in Spanish Populations, Nutrients, doi:10.3390/nu14112254.mdpi.com, doi.org.

13. Galmés (B) et al., Current State of Evidence: Influence of Nutritional and Nutrigenetic Factors on Immunity in the COVID-19 Pandemic Framework, Nutrients, doi:10.3390/nu12092738.mdpi.com, doi.org.

14. EFSA, Scientific Opinion on the substantiation of health claims related to vitamin C and protection of DNA, proteins and lipids from oxidative damage (ID 129, 138, 143, 148), antioxidant function of lutein (ID 146), maintenance of vision (ID 141, 142), collagen formation (ID 130, 131, 136, 137, 149), function of the nervous system (ID 133), function of the immune system (ID 134), function of the immune system during and after extreme physical exercise (ID 144), non-haem iron absorption (ID 132, 147), energy-yielding metabolism (ID 135), and relief in case of irritation in the upper respiratory tract (ID 1714, 1715) pursuant to Article 13(1) of Regulation (EC) No 1924/2006, EFSA Journal, doi:10.2903/j.efsa.2009.1226.europa.eu, doi.org.

15. Boerenkamp et al., Low Levels of Serum and Intracellular Vitamin C in Hospitalized COVID-19 Patients, Nutrients, doi:10.3390/nu15163653.mdpi.com, doi.org.

16. Albóniga et al., Differential abundance of lipids and metabolites related to SARS-CoV-2 infection and susceptibility, Scientific Reports, doi:10.1038/s41598-023-40999-5.nature.com, doi.org.

17. Graydon et al., High baseline frequencies of natural killer cells are associated with asymptomatic SARS-CoV-2 infection, Current Research in Immunology, doi:10.1016/j.crimmu.2023.100064.sciencedirect.com, doi.org.

18. Vojdani et al., In vivo effect of ascorbic acid on enhancement of human natural killer cell activity, Nutrition Research, doi:10.1016/S0271-5317(05)80799-7.sciencedirect.com, doi.org.

Zuo et al., 15 Jul 2022, China, peer-reviewed, 15 authors. Contact: huizheng@suda.edu.cn (corresponding author).

This Paper Vitamin C All

Abstract: bioRxiv preprint doi: https://doi.org/10.1101/2022.07.14.499651; this version posted July 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Vitamin C is an efficient natural product for prevention of 2 SARS-CoV-2 infection by targeting ACE2 in both cell and in 3 vivo mouse models 4 5 Yibo Zuo,1,2 Zhijin Zheng,1,2 Yingkang Huang,5 Jiuyi He,1,2 Lichao Zang,4 6 Tengfei Ren,1,2 Xinhua Cao,1,2 Ying Miao,1,2 Yukang Yuan,1,2 Yanli Liu,3 Feng 7 Ma,5 Sheng Tian,3 Jianfeng Dai,1,2 Qiang Ding,6 Hui Zheng1,2,7,* 8 9 1 International Institute of Infection and Immunity, Institutes of Biology and Medical 10 Sciences, Suzhou 11 2 Jiangsu Key Laboratory of Infection and Immunity, Suzhou 12 3 College of Pharmaceutical Sciences, Suzhou 13 4 The Third Affiliated Hospital of Soochow University, Changzhou 14 Soochow University, Jiangsu 215123, China 15 5 16 of Medical Sciences and Peking Union Medical College, Beijing 10005; Suzhou 17 Institute of Systems Medicine, Jiangsu 215123, China 18 6 19 Innovation Center for Structural Biology, Tsinghua University, Beijing 10084, China 20 7 21 *Correspondence: huizheng@suda.edu.cn CAMS Key Laboratory of Synthetic Biology Regulatory Elements, Chinese Academy Center for Infectious Disease Research, School of Medicine, Beijing Advanced Lead contact 22 23 24 1 bioRxiv preprint doi: https://doi.org/10.1101/2022.07.14.499651; this version posted July 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 25 SUMMARY 26 ACE2 is a major receptor for cell entry of SARS-CoV-2. Despite advances in 27 targeting ACE2 to inhibit SARS-CoV-2's binding, how to efficiently and flexibly 28 control ACE2 levels for prevention of SARS-CoV-2 infection has not been 29 explored. Here, we revealed Vitamin C (VitC) administration as an effective 30 strategy to prevent SARS-CoV-2 infection. VitC reduced ACE2 protein levels in 31 a dose-dependent manner, while partial reduction of ACE2 can greatly restrict 32 SARS-CoV-2 infection. Further studies uncovered that USP50 is a crucial 33 regulator of ACE2 protein levels, and VitC blocks the USP50-ACE2 interaction, 34 thus promoting K48-linked polyubiquitination at Lys788 and degradation of 35 ACE2, without disrupting ACE2 transcriptional expression. Importantly, VitC 36 administration reduced host ACE2 and largely blocked SARS-CoV-2 infection 37 in mice. This study identified an in vivo ACE2 balance controlled by both 38 USP50 and an essential nutrient VitC, and revealed a critical role and 39 application of VitC in daily protection from SARS-CoV-2 infection. 40 41 Highlights 42 VitC reduces ACE2 protein levels in a dose-dependent manner 43 VitC and USP50 regulate K48-linked ubiquitination at Lys788 of ACE2 44 VitC blocks the interaction between USP50 and ACE2 45 VitC administration lowers host ACE2 and prevents SARS-CoV-2 infection 46 in vivo 47 48 2 bioRxiv preprint doi: https://doi.org/10.1101/2022.07.14.499651; this version posted July 15, 2022. The copyright holder for this preprint (which was not certified by..

{ 'indexed': {'date-parts': [[2023, 3, 7]], 'date-time': '2023-03-07T05:37:31Z', 'timestamp': 1678167451182}, 'reference-count': 46, 'publisher': 'EMBO', 'license': [ { 'start': { 'date-parts': [[2023, 3, 6]], 'date-time': '2023-03-06T00:00:00Z', 'timestamp': 1678060800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}, { 'start': { 'date-parts': [[2023, 3, 6]], 'date-time': '2023-03-06T00:00:00Z', 'timestamp': 1678060800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'http://doi.wiley.com/10.1002/tdm_license_1.1'}], 'funder': [ { 'DOI': '10.13039/501100001809', 'name': 'National Natural Science Foundation of China', 'doi-asserted-by': 'publisher', 'award': ['31970846', '32100568']}, { 'DOI': '10.13039/501100012246', 'name': 'Priority Academic Program Development of Jiangsu Higher Education Institutions', 'doi-asserted-by': 'publisher'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.15252/embr.202256374', 'type': 'journal-article', 'created': {'date-parts': [[2023, 3, 6]], 'date-time': '2023-03-06T10:49:56Z', 'timestamp': 1678099796000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Vitamin C promotes ACE2 degradation and protects against SARS‐CoV‐2 infection', 'prefix': '10.15252', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-1908-6054', 'authenticated-orcid': False, 'given': 'Yibo', 'family': 'Zuo', 'sequence': 'first', 'affiliation': [ { 'name': 'International Institute of Infection and Immunity Institutes of ' 'Biology and Medical Sciences, Soochow University Suzhou China'}, { 'name': 'Jiangsu Key Laboratory of Infection and Immunity, Soochow ' 'University Suzhou China'}]}, { 'given': 'Zhijin', 'family': 'Zheng', 'sequence': 'additional', 'affiliation': [ { 'name': 'International Institute of Infection and Immunity Institutes of ' 'Biology and Medical Sciences, Soochow University Suzhou China'}, { 'name': 'Jiangsu Key Laboratory of Infection and Immunity, Soochow ' 'University Suzhou China'}]}, { 'given': 'Yingkang', 'family': 'Huang', 'sequence': 'additional', 'affiliation': [ { 'name': 'CAMS Key Laboratory of Synthetic Biology Regulatory Elements ' 'Chinese Academy of Medical Sciences and Peking Union Medical ' 'College Beijing China'}, {'name': 'Suzhou Institute of Systems Medicine Suzhou China'}]}, { 'given': 'Jiuyi', 'family': 'He', 'sequence': 'additional', 'affiliation': [ { 'name': 'International Institute of Infection and Immunity Institutes of ' 'Biology and Medical Sciences, Soochow University Suzhou China'}, { 'name': 'Jiangsu Key Laboratory of Infection and Immunity, Soochow ' 'University Suzhou China'}]}, { 'given': 'Lichao', 'family': 'Zang', 'sequence': 'additional', 'affiliation': [ { 'name': 'The Third Affiliated Hospital of Soochow University, Changzhou ' 'Soochow University Suzhou China'}]}, { 'given': 'Tengfei', 'family': 'Ren', 'sequence': 'additional', 'affiliation': [ { 'name': 'International Institute of Infection and Immunity Institutes of ' 'Biology and Medical Sciences, Soochow University Suzhou China'}, { 'name': 'Jiangsu Key Laboratory of Infection and Immunity, Soochow ' 'University Suzhou China'}]}, { 'given': 'Xinhua', 'family': 'Cao', 'sequence': 'additional', 'affiliation': [ { 'name': 'International Institute of Infection and Immunity Institutes of ' 'Biology and Medical Sciences, Soochow University Suzhou China'}, { 'name': 'Jiangsu Key Laboratory of Infection and Immunity, Soochow ' 'University Suzhou China'}]}, { 'given': 'Ying', 'family': 'Miao', 'sequence': 'additional', 'affiliation': [ { 'name': 'International Institute of Infection and Immunity Institutes of ' 'Biology and Medical Sciences, Soochow University Suzhou China'}, { 'name': 'Jiangsu Key Laboratory of Infection and Immunity, Soochow ' 'University Suzhou China'}]}, { 'ORCID': 'http://orcid.org/0000-0003-3153-2408', 'authenticated-orcid': False, 'given': 'Yukang', 'family': 'Yuan', 'sequence': 'additional', 'affiliation': [ { 'name': 'International Institute of Infection and Immunity Institutes of ' 'Biology and Medical Sciences, Soochow University Suzhou China'}, { 'name': 'Jiangsu Key Laboratory of Infection and Immunity, Soochow ' 'University Suzhou China'}]}, { 'given': 'Yanli', 'family': 'Liu', 'sequence': 'additional', 'affiliation': [ { 'name': 'College of Pharmaceutical Sciences, Soochow University Suzhou ' 'China'}]}, { 'ORCID': 'http://orcid.org/0000-0002-2975-0118', 'authenticated-orcid': False, 'given': 'Feng', 'family': 'Ma', 'sequence': 'additional', 'affiliation': [ { 'name': 'CAMS Key Laboratory of Synthetic Biology Regulatory Elements ' 'Chinese Academy of Medical Sciences and Peking Union Medical ' 'College Beijing China'}, {'name': 'Suzhou Institute of Systems Medicine Suzhou China'}]}, { 'ORCID': 'http://orcid.org/0000-0002-1871-8390', 'authenticated-orcid': False, 'given': 'Jianfeng', 'family': 'Dai', 'sequence': 'additional', 'affiliation': [ { 'name': 'International Institute of Infection and Immunity Institutes of ' 'Biology and Medical Sciences, Soochow University Suzhou China'}, { 'name': 'Jiangsu Key Laboratory of Infection and Immunity, Soochow ' 'University Suzhou China'}]}, { 'given': 'Sheng', 'family': 'Tian', 'sequence': 'additional', 'affiliation': [ { 'name': 'College of Pharmaceutical Sciences, Soochow University Suzhou ' 'China'}]}, { 'given': 'Qiang', 'family': 'Ding', 'sequence': 'additional', 'affiliation': [ { 'name': 'Center for Infectious Disease Research, School of Medicine, ' 'Beijing Advanced Innovation Center for Structural Biology ' 'Tsinghua University Beijing China'}]}, { 'ORCID': 'http://orcid.org/0000-0002-4325-4946', 'authenticated-orcid': False, 'given': 'Hui', 'family': 'Zheng', 'sequence': 'additional', 'affiliation': [ { 'name': 'International Institute of Infection and Immunity Institutes of ' 'Biology and Medical Sciences, Soochow University Suzhou China'}, { 'name': 'Jiangsu Key Laboratory of Infection and Immunity, Soochow ' 'University Suzhou China'}]}], 'member': '79', 'published-online': {'date-parts': [[2023, 3, 6]]}, 'reference': [ { 'key': 'e_1_2_9_2_1', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1136/jim-2017-000622', 'article-title': 'Induction of deubiquitinating enzyme USP50 during erythropoiesis and ' 'its potential role in the regulation of Ku70 stability', 'volume': '66', 'author': 'Cai J', 'year': '2018', 'journal-title': 'J Investig Med'}, { 'key': 'e_1_2_9_3_1', 'doi-asserted-by': 'crossref', 'first-page': '763', 'DOI': '10.1080/14712598.2022.2078160', 'article-title': 'Therapeutic monoclonal antibodies for COVID‐19 management: an update', 'volume': '22', 'author': 'Chavda VP', 'year': '2022', 'journal-title': 'Expert Opin Biol Ther'}, { 'key': 'e_1_2_9_4_1', 'doi-asserted-by': 'crossref', 'first-page': '13604', 'DOI': '10.1073/pnas.0506390102', 'article-title': 'Pharmacologic ascorbic acid concentrations selectively kill cancer ' 'cells: action as a pro‐drug to deliver hydrogen peroxide to tissues', 'volume': '102', 'author': 'Chen Q', 'year': '2005', 'journal-title': 'Proc Natl Acad Sci USA'}, { 'key': 'e_1_2_9_5_1', 'doi-asserted-by': 'crossref', 'first-page': '822', 'DOI': '10.1038/nature00786', 'article-title': 'Angiotensin‐converting enzyme 2 is an essential regulator of heart ' 'function', 'volume': '417', 'author': 'Crackower MA', 'year': '2002', 'journal-title': 'Nature'}, { 'key': 'e_1_2_9_6_1', 'doi-asserted-by': 'crossref', 'first-page': 'E1‐9', 'DOI': '10.1161/01.RES.87.5.e1', 'article-title': 'A novel angiotensin‐converting enzyme‐related carboxypeptidase (ACE2) ' 'converts angiotensin I to angiotensin 1‐9', 'volume': '87', 'author': 'Donoghue M', 'year': '2000', 'journal-title': 'Circ Res'}, { 'key': 'e_1_2_9_7_1', 'doi-asserted-by': 'crossref', 'first-page': '116', 'DOI': '10.1038/s41585-021-00542-5', 'article-title': 'Implications of testicular ACE2 and the renin‐angiotensin system for ' 'SARS‐CoV‐2 on testis function', 'volume': '19', 'author': 'Edenfield RC', 'year': '2022', 'journal-title': 'Nat Rev Urol'}, { 'key': 'e_1_2_9_8_1', 'doi-asserted-by': 'crossref', 'first-page': '2605', 'DOI': '10.1161/CIRCULATIONAHA.104.510461', 'article-title': 'Effect of angiotensin‐converting enzyme inhibition and angiotensin II ' 'receptor blockers on cardiac angiotensin‐converting enzyme 2', 'volume': '111', 'author': 'Ferrario CM', 'year': '2005', 'journal-title': 'Circulation'}, { 'key': 'e_1_2_9_9_1', 'doi-asserted-by': 'crossref', 'first-page': '7020', 'DOI': '10.18632/aging.202557', 'article-title': 'The efficiency and safety of high‐dose vitamin C in patients with ' 'COVID‐19: a retrospective cohort study', 'volume': '13', 'author': 'Gao D', 'year': '2021', 'journal-title': 'Aging'}, { 'key': 'e_1_2_9_10_1', 'doi-asserted-by': 'crossref', 'first-page': 'e59177', 'DOI': '10.7554/eLife.59177', 'article-title': 'A mechanistic model and therapeutic interventions for COVID‐19 ' 'involving a RAS‐mediated bradykinin storm', 'volume': '9', 'author': 'Garvin MR', 'year': '2020', 'journal-title': 'eLife'}, { 'key': 'e_1_2_9_11_1', 'doi-asserted-by': 'crossref', 'first-page': '1708', 'DOI': '10.1056/NEJMoa2002032', 'article-title': 'Clinical characteristics of coronavirus disease 2019 in China', 'volume': '382', 'author': 'Guan WJ', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': 'e_1_2_9_12_1', 'doi-asserted-by': 'crossref', 'first-page': '1017', 'DOI': '10.1038/s41591-020-0968-3', 'article-title': 'Extrapulmonary manifestations of COVID‐19', 'volume': '26', 'author': 'Gupta A', 'year': '2020', 'journal-title': 'Nat Med'}, { 'key': 'e_1_2_9_13_1', 'doi-asserted-by': 'crossref', 'first-page': '271', 'DOI': '10.1016/j.cell.2020.02.052', 'article-title': 'SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a ' 'clinically proven protease inhibitor', 'volume': '181', 'author': 'Hoffmann M', 'year': '2020', 'journal-title': 'Cell'}, { 'key': 'e_1_2_9_14_1', 'doi-asserted-by': 'crossref', 'first-page': 'D512', 'DOI': '10.1093/nar/gku1267', 'article-title': 'PhosphoSitePlus, 2014: mutations, PTMs and recalibrations', 'volume': '43', 'author': 'Hornbeck PV', 'year': '2015', 'journal-title': 'Nucleic Acids Res'}, { 'key': 'e_1_2_9_15_1', 'unstructured': 'HornbeckPV ZhangB MurrayB KornhauserJM LathamV ' 'SkrzypekE(2015b)PhosphoSitePlus ACE2 ' 'human(https://www.phosphosite.org/proteinAction.action?id=14935&showAllSites=true). ' '[DATASET]'}, { 'key': 'e_1_2_9_16_1', 'doi-asserted-by': 'crossref', 'first-page': 'e1009439', 'DOI': '10.1371/journal.ppat.1009439', 'article-title': 'A novel cell culture system modeling the SARS‐CoV‐2 life cycle', 'volume': '17', 'author': 'Ju X', 'year': '2021', 'journal-title': 'PLoS Pathog'}, { 'key': 'e_1_2_9_17_1', 'doi-asserted-by': 'crossref', 'first-page': '146', 'DOI': '10.1038/375146a0', 'article-title': 'Male‐female differences in fertility and blood pressure in ' 'ACE‐deficient mice', 'volume': '375', 'author': 'Krege JH', 'year': '1995', 'journal-title': 'Nature'}, { 'key': 'e_1_2_9_18_1', 'doi-asserted-by': 'crossref', 'first-page': '271', 'DOI': '10.1016/j.coph.2006.03.001', 'article-title': 'Angiotensin‐converting enzyme 2 in lung diseases', 'volume': '6', 'author': 'Kuba K', 'year': '2006', 'journal-title': 'Curr Opin Pharmacol'}, { 'key': 'e_1_2_9_19_1', 'doi-asserted-by': 'crossref', 'first-page': '1377', 'DOI': '10.3892/ijo.2015.2840', 'article-title': 'SIAH1‐induced p34SEI‐1 polyubiquitination/degradation mediates p53 ' 'preferential vitamin C cytotoxicity', 'volume': '46', 'author': 'Lee S', 'year': '2015', 'journal-title': 'Int J Oncol'}, { 'key': 'e_1_2_9_20_1', 'doi-asserted-by': 'crossref', 'first-page': '3704', 'DOI': '10.1073/pnas.93.8.3704', 'article-title': 'Vitamin C pharmacokinetics in healthy volunteers: evidence for a ' 'recommended dietary allowance', 'volume': '93', 'author': 'Levine M', 'year': '1996', 'journal-title': 'Proc Natl Acad Sci USA'}, { 'key': 'e_1_2_9_21_1', 'doi-asserted-by': 'crossref', 'first-page': '2269', 'DOI': '10.1080/22221751.2020.1830715', 'article-title': 'Establishment of replication‐competent vesicular stomatitis virus‐based ' 'recombinant viruses suitable for SARS‐CoV‐2 entry and neutralization ' 'assays', 'volume': '9', 'author': 'Li H', 'year': '2020', 'journal-title': 'Emerg Microbes Infect'}, { 'key': 'e_1_2_9_22_1', 'doi-asserted-by': 'crossref', 'first-page': '45', 'DOI': '10.1186/s40249-020-00662-x', 'article-title': 'Expression of the SARS‐CoV‐2 cell receptor gene ACE2 in a wide variety ' 'of human tissues', 'volume': '9', 'author': 'Li MY', 'year': '2020', 'journal-title': 'Infect Dis Poverty'}, { 'key': 'e_1_2_9_23_1', 'doi-asserted-by': 'crossref', 'first-page': '976', 'DOI': '10.7150/thno.63751', 'article-title': 'Mitochondrial STAT3 exacerbates LPS‐induced sepsis by driving ' 'CPT1a‐mediated fatty acid oxidation', 'volume': '12', 'author': 'Li R', 'year': '2022', 'journal-title': 'Theranostics'}, { 'key': 'e_1_2_9_24_1', 'doi-asserted-by': 'crossref', 'first-page': '2860', 'DOI': '10.3390/nu5082860', 'article-title': 'Regulation of vitamin C homeostasis during deficiency', 'volume': '5', 'author': 'Lindblad M', 'year': '2013', 'journal-title': 'Nutrients'}, { 'key': 'e_1_2_9_25_1', 'doi-asserted-by': 'crossref', 'first-page': '2412', 'DOI': '10.3390/nu11102412', 'article-title': 'The pharmacokinetics of vitamin C', 'volume': '11', 'author': 'Lykkesfeldt J', 'year': '2019', 'journal-title': 'Nutrients'}, { 'key': 'e_1_2_9_26_1', 'doi-asserted-by': 'crossref', 'first-page': '1474', 'DOI': '10.1016/j.jacc.2018.01.058', 'article-title': 'Angiotensin‐converting enzyme inhibitors in hypertension: to use or not ' 'to use?', 'volume': '71', 'author': 'Messerli FH', 'year': '2018', 'journal-title': 'J Am Coll Cardiol'}, { 'key': 'e_1_2_9_27_1', 'doi-asserted-by': 'crossref', 'first-page': '47', 'DOI': '10.15406/jlprr.2021.08.00250', 'article-title': 'Regulation of ACE‐2 enzyme by hyperoxia in lung epithelial cells by ' 'post‐translational modification', 'volume': '8', 'author': 'Mohamed T', 'year': '2021', 'journal-title': 'J Lung Pulm Respir Res'}, { 'key': 'e_1_2_9_28_1', 'doi-asserted-by': 'crossref', 'first-page': '343', 'DOI': '10.1111/bcpt.12323', 'article-title': 'Elimination of ascorbic acid after high‐dose infusion in prostate ' 'cancer patients: a pharmacokinetic evaluation', 'volume': '116', 'author': 'Nielsen TK', 'year': '2015', 'journal-title': 'Basic Clin Pharmacol Toxicol'}, { 'key': 'e_1_2_9_29_1', 'doi-asserted-by': 'crossref', 'first-page': '533', 'DOI': '10.7326/0003-4819-140-7-200404060-00010', 'article-title': 'Vitamin C pharmacokinetics: implications for oral and intravenous use', 'volume': '140', 'author': 'Padayatty SJ', 'year': '2004', 'journal-title': 'Ann Intern Med'}, { 'key': 'e_1_2_9_30_1', 'doi-asserted-by': 'crossref', 'first-page': '102324', 'DOI': '10.1016/j.dsx.2021.102324', 'article-title': 'Vitamin C and COVID‐19 treatment: a systematic review and meta‐analysis ' 'of randomized controlled trials', 'volume': '15', 'author': 'Rawat D', 'year': '2021', 'journal-title': 'Diabetes Metab Syndr'}, { 'key': 'e_1_2_9_31_1', 'doi-asserted-by': 'crossref', 'first-page': '4763', 'DOI': '10.1038/ncomms5763', 'article-title': 'Screening of DUB activity and specificity by MALDI‐TOF mass ' 'spectrometry', 'volume': '5', 'author': 'Ritorto MS', 'year': '2014', 'journal-title': 'Nat Commun'}, { 'key': 'e_1_2_9_32_1', 'doi-asserted-by': 'crossref', 'first-page': '1301', 'DOI': '10.2174/1389450117666160727142401', 'article-title': 'The anti‐inflammatory potential of ACE2/Angiotensin‐(1‐7)/Mas receptor ' 'axis: evidence from basic and clinical research', 'volume': '18', 'author': 'Rodrigues Prestes TR', 'year': '2017', 'journal-title': 'Curr Drug Targets'}, { 'key': 'e_1_2_9_33_1', 'doi-asserted-by': 'crossref', 'first-page': '768', 'DOI': '10.1002/ddr.21679', 'article-title': 'Telmisartan as tentative angiotensin receptor blocker therapeutic for ' 'COVID‐19', 'volume': '81', 'author': 'Rothlin RP', 'year': '2020', 'journal-title': 'Drug Dev Res'}, { 'key': 'e_1_2_9_34_1', 'doi-asserted-by': 'crossref', 'first-page': '1190', 'DOI': '10.1161/CIRCULATIONAHA.120.048191', 'article-title': 'MDM2‐mediated ubiquitination of angiotensin‐converting enzyme 2 ' 'contributes to the development of pulmonary arterial hypertension', 'volume': '142', 'author': 'Shen H', 'year': '2020', 'journal-title': 'Circulation'}, { 'key': 'e_1_2_9_35_1', 'doi-asserted-by': 'crossref', 'first-page': '139', 'DOI': '10.1007/s00280-013-2179-9', 'article-title': 'Phase I clinical trial to evaluate the safety, tolerability, and ' 'pharmacokinetics of high‐dose intravenous ascorbic acid in patients ' 'with advanced cancer', 'volume': '72', 'author': 'Stephenson CM', 'year': '2013', 'journal-title': 'Cancer Chemother Pharmacol'}, { 'key': 'e_1_2_9_36_1', 'doi-asserted-by': 'crossref', 'first-page': '247', 'DOI': '10.1038/s41580-020-0242-z', 'article-title': 'Mechano‐genomic regulation of coronaviruses and its interplay with ' 'ageing', 'volume': '21', 'author': 'Uhler C', 'year': '2020', 'journal-title': 'Nat Rev Mol Cell Biol'}, { 'key': 'e_1_2_9_37_1', 'doi-asserted-by': 'crossref', 'first-page': '742', 'DOI': '10.2174/157016110793563924', 'article-title': 'Angiotensin converting enzyme inhibitors and angiotensin receptor ' 'blockers in the treatment of hypertension: should they be used ' 'together?', 'volume': '8', 'author': 'Verdecchia P', 'year': '2010', 'journal-title': 'Curr Vasc Pharmacol'}, { 'key': 'e_1_2_9_38_1', 'doi-asserted-by': 'crossref', 'first-page': 'e02165‐17', 'DOI': '10.1128/AAC.02165-17', 'article-title': 'Vitamin C potentiates the killing of mycobacterium tuberculosis by the ' 'first‐line tuberculosis drugs isoniazid and rifampin in mice', 'volume': '62', 'author': 'Vilcheze C', 'year': '2018', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': 'e_1_2_9_39_1', 'doi-asserted-by': 'crossref', 'first-page': '252', 'DOI': '10.1007/s11684-021-0837-6', 'article-title': 'Degradation of SARS‐CoV‐2 receptor ACE2 by the E3 ubiquitin ligase Skp2 ' 'in lung epithelial cells', 'volume': '15', 'author': 'Wang G', 'year': '2021', 'journal-title': 'Front Med'}, { 'key': 'e_1_2_9_40_1', 'doi-asserted-by': 'crossref', 'first-page': '788', 'DOI': '10.1038/s41401-021-00735-z', 'article-title': 'Discovery of potential small molecular SARS‐CoV‐2 entry blockers ' 'targeting the spike protein', 'volume': '43', 'author': 'Wang L', 'year': '2022', 'journal-title': 'Acta Pharmacol Sin'}, { 'key': 'e_1_2_9_41_1', 'doi-asserted-by': 'crossref', 'first-page': '1080', 'DOI': '10.1053/j.ajkd.2005.08.018', 'article-title': 'Underuse of ACE inhibitors and angiotensin II receptor blockers in ' 'elderly patients with diabetes', 'volume': '46', 'author': 'Winkelmayer WC', 'year': '2005', 'journal-title': 'Am J Kidney Dis'}, { 'key': 'e_1_2_9_42_1', 'doi-asserted-by': 'crossref', 'first-page': '1260', 'DOI': '10.1126/science.abb2507', 'article-title': 'Cryo‐EM structure of the 2019‐nCoV spike in the prefusion conformation', 'volume': '367', 'author': 'Wrapp D', 'year': '2020', 'journal-title': 'Science'}, { 'key': 'e_1_2_9_43_1', 'doi-asserted-by': 'crossref', 'first-page': '609', 'DOI': '10.1038/s41422-022-00672-4', 'article-title': 'Structural and biochemical mechanism for increased infectivity and ' 'immune evasion of omicron BA.2 variant compared to BA.1 and their ' 'possible mouse origins', 'volume': '32', 'author': 'Xu Y', 'year': '2022', 'journal-title': 'Cell Res'}, { 'key': 'e_1_2_9_44_1', 'doi-asserted-by': 'crossref', 'first-page': '676', 'DOI': '10.1021/acschemneuro.1c00845', 'article-title': 'Vitamin C inhibits ubiquitination of glutamate transporter 1 (GLT‐1) in ' 'astrocytes by downregulating HECTD1', 'volume': '13', 'author': 'Zeng X', 'year': '2022', 'journal-title': 'ACS Chem Nerosci'}, { 'key': 'e_1_2_9_45_1', 'doi-asserted-by': 'crossref', 'first-page': '1016', 'DOI': '10.1016/j.cell.2020.04.035', 'article-title': 'SARS‐CoV‐2 receptor ACE2 is an interferon‐stimulated Gene in human ' 'airway epithelial cells and is detected in specific cell subsets across ' 'tissues', 'volume': '181', 'author': 'Ziegler CGK', 'year': '2020', 'journal-title': 'Cell'}, { 'key': 'e_1_2_9_46_1', 'doi-asserted-by': 'crossref', 'first-page': '1146', 'DOI': '10.1038/s41467-020-14948-z', 'article-title': 'Regulation of the linear ubiquitination of STAT1 controls antiviral ' 'interferon signaling', 'volume': '11', 'author': 'Zuo Y', 'year': '2020', 'journal-title': 'Nat Commun'}, { 'key': 'e_1_2_9_47_1', 'doi-asserted-by': 'crossref', 'first-page': 'eabj3887', 'DOI': '10.1126/sciadv.abj3887', 'article-title': 'LATS1 is a central signal transmitter for achieving full type‐I ' 'interferon activity', 'volume': '8', 'author': 'Zuo Y', 'year': '2022', 'journal-title': 'Sci Adv'}], 'container-title': 'EMBO reports', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.15252/embr.202256374', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.15252/embr.202256374', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.15252/embr.202256374', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 3, 6]], 'date-time': '2023-03-06T10:50:18Z', 'timestamp': 1678099818000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.15252/embr.202256374'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 3, 6]]}, 'references-count': 46, 'alternative-id': ['10.15252/embr.202256374'], 'URL': 'http://dx.doi.org/10.15252/embr.202256374', 'relation': {}, 'ISSN': ['1469-221X', '1469-3178'], 'subject': ['Genetics', 'Molecular Biology', 'Biochemistry'], 'container-title-short': 'EMBO Reports', 'published': {'date-parts': [[2023, 3, 6]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0